

ABSTRACT

Neuro Oncol. 2022 Aug 12;noac196. doi: 10.1093/neuonc/noac196. Online ahead of print.

European Association of Neuro-Oncology (EANO) Guidelines for Treatment of Primary Central Nervous System Lymphoma (PCNSL).

Hoang-Xuan K(1), Deckert M(2), Ferreri AJM(3), Furtner J(4), Gallego Perez-Larraya J(5), Henriksson R(6), Hottinger AF(7), Kasenda B(8), Lefranc F(9), Lossos A(10), McBain C(11), Preusser M(12), Roth P(13), Rudà R(14)(15), Schlegel U(16), Soffietti R(15), Soussain C(17), Taphoorn MJB(18), Touitou V(19), Weller M(13), Bromberg JEC(20).

Author information:

- (1)APHP, Department of Neurology, Groupe Hospitalier Pitié-Salpêtrière; Sorbonne Université; IHU; ICM. Paris, France.
- (2)Institute of Neuropathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- (3)Lymphoma Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy.
- (4)Department of Biomedical and Imaging Image-guided Therapy Medical University of Vienna, Vienna, Austria.
- (5)Health Research Institute of Navarra (IdiSNA), Program in Solid Tumors, Foundation for the Applied Medical Research, Department of Neurology, Clínica Universidad de Navarra, Pamplona, Navarra, Spain.
- (6)Department of Radiation Sciences, Oncology, University of Umeå, S-901 85 Umeå, Sweden.
- (7)Departments of Oncology & Clinical Neurosciences, CHUV University Hospital Lausanne & University of Lausanne, Lausanne Switzerland.
- (8)Department of Hematology/Oncology and Palliative Care, Klinikum Stuttgart, Stuttgart, Germany.
- (9)Department of Neurosurgery, Hôpital Erasme, Université Libre de Bruxelles, Belgium.
- (10)Head, Leslie and Michael Gaffin Center for Neuro-Oncology ; Departments of Oncology and Neurology ; Hadassah-Hebrew University Medical Center; Jerusalem, Israel.
- (11)Department of Clinical Oncology, The Christie NHS FT; Manchester; United Kingdom.
- (12)Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna Austria.
- (13)Department of Neurology & Brain Tumor Center, University Hospital and University of Zurich, Zurich, Switzerland.
- (14)Department of Neurology, Castelfranco Veneto/Treviso Hospital, Italy.
- (15)Division of Neuro-Oncology, Department of Neuroscience, University of Turin, and City of Health and Science University Hospital, Turin, Italy.
- (16)Universitätsklinikum Knappschaftskrankenhaus Bochum GmbH, Germany.
- (17)Department of Hematology, Institut Curie, Site Saint-Cloud, France and INSERM U932 Institut Curie, PSL Research University, Paris, France.
- (18)Department of Neurology, Leiden University Medical Center and Department of Neurology, Haaglanden Medical Center The Hague, The Netherlands.
- (19)APHP, Department of Ophtalmology, Groupe Hospitalier Pitié-Salpêtrière; Sorbonne Université. Paris, France.
- (20)Department of Neuro-Oncology, Erasmus MC University Medical Center Cancer Institute, Rotterdam. The Netherlands.

The management of primary central nervous system (PCNSL) is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the limited number of controlled studies available. In 2021, given recent advances and publication of practice-changing randomised trials, the European Association of Neuro-Oncology (EANO) created a multidisciplinary task force to update the previously published evidence-based guidelines for immunocompetent adult patients with PCNSL and added a section on immunosuppressed patients. The

guideline provides consensus considerations and recommendations for treatment of PCNSL, including intraocular manifestations and specific management of elderly . The main changes from the previous guideline include strengthened evidence for the consolidation with ASCT in first-line treatment, prospectively assessed chemotherapy combinations for both young and elderly patients, clarification of the role of rituximab even though the data remain inconclusive, of the role of new agents, and the incorporation of immunosuppressed patients and primary ocular lymphoma. The guideline should aid the clinicians in everyday practice and decision making and serve as a basis for future research in the field.

© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

DOI: 10.1093/neuonc/noac196

PMID: 35953526